Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Time to Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down prior to trading on Tuesday . The stock had previously closed at $77.00, but opened at $73.10. Zealand Pharma A/S shares last traded at $74.00, with a volume of 2,240 shares.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ZLDPF. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. BTIG Research upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. Finally, Zacks Research raised shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 15th. Six investment analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Zealand Pharma A/S currently has an average rating of “Strong Buy”.

Zealand Pharma A/S Stock Down 3.9%

The company has a debt-to-equity ratio of 0.02, a current ratio of 14.10 and a quick ratio of 14.10. The stock has a 50 day simple moving average of $76.67 and a 200-day simple moving average of $68.33. The firm has a market cap of $5.26 billion, a PE ratio of 5.32 and a beta of 0.72.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.21. The firm had revenue of $7.76 million during the quarter, compared to analyst estimates of $4.54 million. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%. Sell-side analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.